167 related articles for article (PubMed ID: 34253166)
21. Inhibition of IL-6-JAK/Stat3 signaling in castration-resistant prostate cancer cells enhances the NK cell-mediated cytotoxicity via alteration of PD-L1/NKG2D ligand levels.
Xu L; Chen X; Shen M; Yang DR; Fang L; Weng G; Tsai Y; Keng PC; Chen Y; Lee SO
Mol Oncol; 2018 Mar; 12(3):269-286. PubMed ID: 28865178
[TBL] [Abstract][Full Text] [Related]
22. The crosstalk between endometrial stromal cells and macrophages impairs cytotoxicity of NK cells in endometriosis by secreting IL-10 and TGF-β.
Yang HL; Zhou WJ; Chang KK; Mei J; Huang LQ; Wang MY; Meng Y; Ha SY; Li DJ; Li MQ
Reproduction; 2017 Dec; 154(6):815-825. PubMed ID: 28971893
[TBL] [Abstract][Full Text] [Related]
23. Cervical cancer cell lines expressing NKG2D-ligands are able to down-modulate the NKG2D receptor on NKL cells with functional implications.
Jimenez-Perez MI; Jave-Suarez LF; Ortiz-Lazareno PC; Bravo-Cuellar A; Gonzalez-Ramella O; Aguilar-Lemarroy A; Hernandez-Flores G; Pereira-Suarez AL; Daneri-Navarro A; del Toro-Arreola S
BMC Immunol; 2012 Feb; 13():7. PubMed ID: 22316211
[TBL] [Abstract][Full Text] [Related]
24. IL-2/IL-18 prevent the down-modulation of NKG2D by TGF-beta in NK cells via the c-Jun N-terminal kinase (JNK) pathway.
Song H; Hur DY; Kim KE; Park H; Kim T; Kim CW; Bang S; Cho DH
Cell Immunol; 2006 Jul; 242(1):39-45. PubMed ID: 17070508
[TBL] [Abstract][Full Text] [Related]
25. TGF-β regulated leukemia cell susceptibility against NK targeting through the down-regulation of the CD48 expression.
Huang CH; Liao YJ; Chiou TJ; Huang HT; Lin YH; Twu YC
Immunobiology; 2019 Sep; 224(5):649-658. PubMed ID: 31421859
[TBL] [Abstract][Full Text] [Related]
26. Intracellular retention of the NKG2D ligand MHC class I chain-related gene A in human melanomas confers immune privilege and prevents NK cell-mediated cytotoxicity.
Fuertes MB; Girart MV; Molinero LL; Domaica CI; Rossi LE; Barrio MM; Mordoh J; Rabinovich GA; Zwirner NW
J Immunol; 2008 Apr; 180(7):4606-14. PubMed ID: 18354183
[TBL] [Abstract][Full Text] [Related]
27. Galunisertib modifies the liver fibrotic composition in the Abcb4Ko mouse model.
Hammad S; Cavalcanti E; Werle J; Caruso ML; Dropmann A; Ignazzi A; Ebert MP; Dooley S; Giannelli G
Arch Toxicol; 2018 Jul; 92(7):2297-2309. PubMed ID: 29808285
[TBL] [Abstract][Full Text] [Related]
28. TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients.
Crane CA; Han SJ; Barry JJ; Ahn BJ; Lanier LL; Parsa AT
Neuro Oncol; 2010 Jan; 12(1):7-13. PubMed ID: 20150362
[TBL] [Abstract][Full Text] [Related]
29. Targeting the TGFβ pathway with galunisertib, a TGFβRI small molecule inhibitor, promotes anti-tumor immunity leading to durable, complete responses, as monotherapy and in combination with checkpoint blockade.
Holmgaard RB; Schaer DA; Li Y; Castaneda SP; Murphy MY; Xu X; Inigo I; Dobkin J; Manro JR; Iversen PW; Surguladze D; Hall GE; Novosiadly RD; Benhadji KA; Plowman GD; Kalos M; Driscoll KE
J Immunother Cancer; 2018 Jun; 6(1):47. PubMed ID: 29866156
[TBL] [Abstract][Full Text] [Related]
30. Inhibition of bromodomain and extra-terminal (BET) proteins increases NKG2D ligand MICA expression and sensitivity to NK cell-mediated cytotoxicity in multiple myeloma cells: role of cMYC-IRF4-miR-125b interplay.
Abruzzese MP; Bilotta MT; Fionda C; Zingoni A; Soriani A; Vulpis E; Borrelli C; Zitti B; Petrucci MT; Ricciardi MR; Molfetta R; Paolini R; Santoni A; Cippitelli M
J Hematol Oncol; 2016 Dec; 9(1):134. PubMed ID: 27903272
[TBL] [Abstract][Full Text] [Related]
31. Effect of platinum‑based chemotherapy on the expression of natural killer group 2 member D ligands, programmed cell death‑1 ligand 1 and HLA class I in non‑small cell lung cancer.
Okita R; Maeda A; Shimizu K; Nojima Y; Saisho S; Nakata M
Oncol Rep; 2019 Aug; 42(2):839-848. PubMed ID: 31173242
[TBL] [Abstract][Full Text] [Related]
32. Anti-transforming growth factor (TGF)-beta antibodies inhibit breast cancer cell tumorigenicity and increase mouse spleen natural killer cell activity. Implications for a possible role of tumor cell/host TGF-beta interactions in human breast cancer progression.
Arteaga CL; Hurd SD; Winnier AR; Johnson MD; Fendly BM; Forbes JT
J Clin Invest; 1993 Dec; 92(6):2569-76. PubMed ID: 7504687
[TBL] [Abstract][Full Text] [Related]
33. Enhanced interaction between natural killer cells and lung cancer cells: involvement in gefitinib-mediated immunoregulation.
He S; Yin T; Li D; Gao X; Wan Y; Ma X; Ye T; Guo F; Sun J; Lin Z; Wang Y
J Transl Med; 2013 Aug; 11():186. PubMed ID: 23937717
[TBL] [Abstract][Full Text] [Related]
34. Effects of transforming growth factor-β inhibitor on the proliferation of glioma stem/progenitor cell.
Zhang Q; Guo W; Di C; Lou M; Li H; Zhao Y
Pol J Pathol; 2017; 68(4):312-317. PubMed ID: 29517201
[TBL] [Abstract][Full Text] [Related]
35. FASN-TGF-β1-PD-L1 axis contributes to the development of resistance to NK cell cytotoxicity of cisplatin-resistant lung cancer cells.
Shen M; Tsai Y; Zhu R; Keng PC; Chen Y; Chen Y; Lee SO
Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Mar; 1863(3):313-322. PubMed ID: 29306075
[TBL] [Abstract][Full Text] [Related]
36. Inhibition of NK cell activity through TGF-beta 1 by down-regulation of NKG2D in a murine model of head and neck cancer.
Dasgupta S; Bhattacharya-Chatterjee M; O'Malley BW; Chatterjee SK
J Immunol; 2005 Oct; 175(8):5541-50. PubMed ID: 16210663
[TBL] [Abstract][Full Text] [Related]
37. Platelet-derived transforming growth factor-beta down-regulates NKG2D thereby inhibiting natural killer cell antitumor reactivity.
Kopp HG; Placke T; Salih HR
Cancer Res; 2009 Oct; 69(19):7775-83. PubMed ID: 19738039
[TBL] [Abstract][Full Text] [Related]
38. The human NKG2D ligand ULBP2 can be expressed at the cell surface with or without a GPI anchor and both forms can activate NK cells.
Fernández-Messina L; Ashiru O; Agüera-González S; Reyburn HT; Valés-Gómez M
J Cell Sci; 2011 Feb; 124(Pt 3):321-7. PubMed ID: 21224393
[TBL] [Abstract][Full Text] [Related]
39. NGS-based transcriptome profiling reveals biomarkers for companion diagnostics of the TGF-β receptor blocker galunisertib in HCC.
Cao Y; Agarwal R; Dituri F; Lupo L; Trerotoli P; Mancarella S; Winter P; Giannelli G
Cell Death Dis; 2017 Feb; 8(2):e2634. PubMed ID: 28230858
[TBL] [Abstract][Full Text] [Related]
40. TGF-β1 down-regulation of NKG2D/DAP10 and 2B4/SAP expression on human NK cells contributes to HBV persistence.
Sun C; Fu B; Gao Y; Liao X; Sun R; Tian Z; Wei H
PLoS Pathog; 2012; 8(3):e1002594. PubMed ID: 22438812
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]